SYNDAX PHARMACEU.DL-,0001

Syndax reported Q2 revenue of $73 million and a loss of $0.55 per share, missing both revenue and earnings expectations. Revenue grew 92% year‑over‑year, driven by Revuforj (net revenue $54.7 million) and Niktimvo (collaboration revenue $18.1 million), and management expects projected annual revenues for both products to be well over $200 million. The company ended the quarter with $575 million in cash, reiterated its operating cost guidance for 2026, and cited several clinical data catalysts for the second half of the year; the stock fell after hours following the missed metrics. » More on de.investing.com

Guggenheim cut its price target for Syndax Pharmaceuticals to $31 from $34 but kept a Buy rating after revising acute myeloid leukemia market assumptions and factoring recent commercial updates. Syndax published Phase 1/2 SAVE results showing an overall response rate of 88% and a 71% composite complete remission rate for a Revuforj, decitabine/cedazuridine and venetoclax oral regimen, with activity across genetic subgroups and a generally manageable safety profile. The analyst also considered Kura Oncology developments when adjusting Syndax's valuation; Syndax remains a commercial-stage company focused on hematologic malignancies. » More on finance.yahoo.com

At the EHA meeting, Syndax presented data from 12 abstracts on Revumenib, including high response rates across several studies: ROAR showed an overall response rate of 82% and a complete remission rate of 64% in heavily pretreated patients; a phase‑1 combination study reported 97% complete remissions in newly diagnosed AML; and the phase‑2 SAVE study achieved an overall response rate of 88% with 68% MRD negativity. An analysis after transplantation showed an estimated 12‑month survival rate of 95%. Revuforj is approved by the FDA; Syndax reported revenue of USD 217 million for the past twelve months, growth of almost 397%. » More on de.investing.com